loading
Adial Pharmaceuticals Inc stock is traded at $0.656, with a volume of 21,887. It is up +3.44% in the last 24 hours and down -16.43% over the past month. Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
See More
Previous Close:
$0.6342
Open:
$0.623
24h Volume:
21,887
Relative Volume:
0.03
Market Cap:
$4.31M
Revenue:
-
Net Income/Loss:
$-6.07M
P/E Ratio:
-0.1135
EPS:
-5.78
Net Cash Flow:
$-7.34M
1W Performance:
-7.61%
1M Performance:
-16.43%
6M Performance:
-32.61%
1Y Performance:
-46.67%
1-Day Range:
Value
$0.6218
$0.656
1-Week Range:
Value
$0.6218
$0.727
52-Week Range:
Value
$0.614
$3.10

Adial Pharmaceuticals Inc Stock (ADIL) Company Profile

Name
Name
Adial Pharmaceuticals Inc
Name
Phone
434-422-9800
Name
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Name
Employee
7
Name
Twitter
@AdialPharma
Name
Next Earnings Date
2024-12-12
Name
Latest SEC Filings
Name
ADIL's Discussions on Twitter

Compare ADIL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ADIL
Adial Pharmaceuticals Inc
0.656 4.31M 0 -6.07M -7.34M -5.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-14-24 Initiated Rodman & Renshaw Buy
Oct-30-18 Initiated Maxim Group Buy
Oct-11-18 Initiated Dawson James Buy

Adial Pharmaceuticals Inc Stock (ADIL) Latest News

pulisher
06:34 AM

Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder - ACCESS Newswire

06:34 AM
pulisher
Mar 31, 2025

Alcohol Use Disorder Treatment Market: Discover the Best - openPR.com

Mar 31, 2025
pulisher
Mar 31, 2025

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 19.8% in March - Defense World

Mar 31, 2025
pulisher
Mar 21, 2025

Adial Pharmaceuticals Appoints Tony Goodman as COO - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Adial Pharmaceuticals appoints new COO Tony Goodman - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Litchfield Hills Research Predicts ADIL Q1 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 13, 2025

Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Grows By 610.2% - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Adial Pharma stock hits 52-week low at $0.69 amid market challenges - Investing.com

Mar 11, 2025
pulisher
Mar 08, 2025

Brookline Capital Management Estimates ADIL Q1 Earnings - Defense World

Mar 08, 2025
pulisher
Mar 05, 2025

Rodman & Renshaw maintains Adial stock Buy rating, $8 target By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 04, 2025

Rodman & Renshaw maintains Adial stock Buy rating, $8 target - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Adial Pharma stock hits 52-week low at $0.71 amid market challenges - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Adial Pharma stock hits 52-week low at $0.71 amid market challenges By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

ADIAL PHARMACEUTICALS, INC. SEC 10-K Report - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

Adial Pharmaceuticals expects cash to fund operations into 2H of 2025 - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Can Adial's FDA-Approved Strategy for Alcohol Treatment Offset Its Widening Losses? - StockTitan

Mar 04, 2025
pulisher
Mar 02, 2025

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia - accessnewswire.com

Feb 27, 2025
pulisher
Feb 27, 2025

Adial Pharmaceuticals Receives Positive FDA Feedback on In Vitro Bridging Strategy for AD04 - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland - ACCESS Newswire

Feb 26, 2025
pulisher
Feb 26, 2025

Adial gets FDA nod for Phase 3 drug strategy By Investing.com - Investing.com Australia

Feb 26, 2025
pulisher
Feb 26, 2025

Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs - AOL.com

Feb 26, 2025
pulisher
Feb 26, 2025

Adial gets FDA nod for Phase 3 drug strategy - Investing.com India

Feb 26, 2025
pulisher
Feb 25, 2025

Adial Pharmaceuticals Receives Positive Response from FDA - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Adial Pharmaceuticals Receives FDA's Positive Feedback On AD04 In Vitro Bridging Strategy - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

Adial Pharmaceuticals Advances AD04 with FDA Approval - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder - Benzinga

Feb 25, 2025
pulisher
Feb 23, 2025

Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City - ACCESS Newswire

Feb 23, 2025
pulisher
Feb 21, 2025

Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare - ACCESS Newswire

Feb 21, 2025
pulisher
Feb 20, 2025

Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 20, 2025

Adial Pharmaceuticals secures patent for genetic addiction treatment By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 19, 2025

Adial Pharmaceuticals Granted New U.S. Patent Expanding - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Adial Granted New U.S. Patent Expanding Genetic-Based Approach For Addiction Treatment - Nasdaq

Feb 19, 2025
pulisher
Feb 19, 2025

Adial Pharmaceuticals secures patent for genetic addiction treatment - Investing.com

Feb 19, 2025
pulisher
Feb 19, 2025

This Groundbreaking Patent Could Transform How We Treat AddictionHere's Why Genetics Matter - StockTitan

Feb 19, 2025
pulisher
Feb 16, 2025

Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria - ACCESS Newswire

Feb 16, 2025
pulisher
Feb 13, 2025

Adial Is Filling The Gap In Alcohol Use Disorder Treatment With Repurposed Drug - Citeline News & Insights

Feb 13, 2025
pulisher
Feb 13, 2025

Adial Pharmaceuticals secures new patent for addiction treatment By Investing.com - Investing.com Nigeria

Feb 13, 2025
pulisher
Feb 13, 2025

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Significant Growth in Short Interest - Defense World

Feb 13, 2025
pulisher
Feb 12, 2025

Adial Pharmaceuticals secures new patent for addiction treatment - Investing.com India

Feb 12, 2025
pulisher
Feb 12, 2025

Adial Pharmaceuticals Awarded U.S. Patent For Genotype-Specific Treatment Of Opioid Disorders - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

Adial Pharmaceuticals Secures Patent for Genetically Targeted Treatment Methods in Addiction Therapy - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

Revolutionary Patent Win: Adial's DNA-Guided Solution Takes On $35B Addiction Crisis - StockTitan

Feb 12, 2025
pulisher
Feb 12, 2025

EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Yahoo Finance

Feb 12, 2025

Adial Pharmaceuticals Inc Stock (ADIL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Cap:     |  Volume (24h):